IFP Advisors’s Lifecore Biomedical LFCR Stock Holding History

IFP Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$7	–	4386
2025 Q1	$7	Hold	1	–	–	﹤0.01%	4252
2024 Q4	$7	Buy	+1	New	+$6	﹤0.01%	4548

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

IFP Advisors's LFCR Position: Q2 2025 in Review

IFP Advisors sold out of Lifecore Biomedical (LFCR) in Q2 2025, closing a stake of 1 share — an estimated $7 sold.

IFP Advisors first reported a position in LFCR in Q4 2024 and held it in 2 quarters. The position peaked at $7 in Q1 2025. 86 funds tracked by Wall St. Rank hold LFCR as of Q2 2025.

IFP Advisors reported no remaining Lifecore Biomedical position as of Q2 2025 after selling out during the quarter.
IFP Advisors sold 1 Lifecore Biomedical share in Q2 2025, an estimated $7.
IFP Advisors first reported a position in Lifecore Biomedical in Q4 2024 and held it in 2 quarters.
IFP Advisors's Lifecore Biomedical position peaked at $7 in Q1 2025.
86 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.